EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Incidence and treatment-modifying impact of immune checkpoint inhibitor–associated peripheral edema: a systematic review and meta-analysis

Anneliese Markus iD, Kazuya Tsuchiya, Toshiaki Takahashi iD, Evelyn Elias MBBCh, Mako Koseki, Yoshito Nishimura iD, Nicholas C Rohs, Yu Fujiwara iD

JNCI Cancer Spectrum · 07.07.2026 · 10 (4)

DOI: 10.1093/jncics/pkag058 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 03.06.2026. Verfasst von Anneliese Markus und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Edema, Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune-related adverse events disrupt immune checkpoint inhibitor therapy and impact quality of life. Peripheral edema is common among patients with cancer, however the causality of peripheral edema can be unclear in the context of multidrug regimens.

Methods

PubMed/MEDLINE, Embase, and Web of Science were searched to identify phase 3 randomized controlled trials (RCTs) evaluating immune checkpoint inhibitors reporting peripheral edema incidence. The incidence of edema was calculated according to adverse event, immune checkpoint inhibitor, and treatment patterns. A random-effects meta-analysis pooled odds ratios (ORs) of edema incidence between immune checkpoint inhibitor and non–immune checkpoint inhibitor groups. A systematic review characterizing the interventions for immune-related peripheral edema was also conducted.

Results

From 58 RCTs (22 590 patients), treatment-related peripheral edema (grade 1-5) occurred in 2.80% (n = 195 of 6969) of patients receiving immune checkpoint inhibitor monotherapy, 4.96% (n = 112 of 2257) of patients receiving immune checkpoint inhibitor with chemotherapy, and 8.73% (n = 205 of 2349) of patients receiving immune checkpoint inhibitor with targeted therapy. Meta-analysis showed immune checkpoint inhibitor monotherapy had lower treatment-related peripheral edema incidence compared with chemotherapy (OR = 0.45, 95% CI = 0.27 to 0.73; P = .001, I2 = 69%) with the lowest relative incidence among programmed cell death protein 1 vs chemotherapy (OR = 0.41, 95% CI = 0.23 to 0.73; P = .003) and immune checkpoint inhibitor vs taxane chemotherapy (OR = 0.32, 95% CI = 0.18 to 0.58; P < .001). A systematic review of treatment outcomes for immune-related peripheral edema among 40 patients (19 studies) revealed 82.5% (n = 33 of 40) of cases received glucocorticoid treatment, and immune checkpoint inhibitors were permanently discontinued in 35% (n = 14 of 40).

Conclusions

Peripheral edema is a rare but potentially serious adverse event associated with immune checkpoint inhibitors. Immune checkpoint inhibitors likely confer less peripheral edema risk than taxane therapy. To avoid unnecessary treatment interruptions, treatment discontinuation requires careful consideration, particularly when edema develops following immune checkpoint inhibitor combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsEdemaNeoplasmsHumansIncidenceRandomized Controlled Trials as TopicAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase III as Topic

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
  • Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, United States.
  • Department of Internal Medicine, Morehouse School of Medicine, Atlanta, GA, United States.
  • Department of Internal Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States.
  • Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Morningside/West, New York, NY, United States.
  • Division of Hematology and Oncology, Mayo Clinic, Rochester, MN, United States.

ORCID-Profile: Anneliese Markus, Toshiaki Takahashi, Yoshito Nishimura, Yu Fujiwara

Zitieren

APA

Markus, A., Tsuchiya, K., Takahashi, T., MBBCh, E. E., Koseki, M., Nishimura, Y., Rohs, N. C., & Fujiwara, Y. (2026). Incidence and treatment-modifying impact of immune checkpoint inhibitor–associated peripheral edema: a systematic review and meta-analysis. JNCI Cancer Spectrum, 10(4). https://doi.org/10.1093/jncics/pkag058

Vancouver

Markus A, Tsuchiya K, Takahashi T, MBBCh EE, Koseki M, Nishimura Y, et al. Incidence and treatment-modifying impact of immune checkpoint inhibitor–associated peripheral edema: a systematic review and meta-analysis. JNCI Cancer Spectrum. 2026;10(4). doi:10.1093/jncics/pkag058

BibTeX
@article{Markus2026,
  author = {Markus, Anneliese and Tsuchiya, Kazuya and Takahashi, Toshiaki and MBBCh, Evelyn Elias and Koseki, Mako and Nishimura, Yoshito and Rohs, Nicholas C and Fujiwara, Yu},
  title = {Incidence and treatment-modifying impact of immune checkpoint inhibitor–associated peripheral edema: a systematic review and meta-analysis},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  volume = {10},
  number = {4},
  doi = {10.1093/jncics/pkag058}
}
Kostenlos starten →